Results 81 to 90 of about 7,154 (184)

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system

, 2022
The oral protease inhibitor nirmatrelvir is of key importance for prevention of severe coronavirus disease 2019 (COVID-19). To facilitate resistance monitoring, we studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escape from ...
Peters, Günther Herbert Johannes, Fernandez-Antunez, Carlota, Zhou, Yuyong, Ramirez, Santseharay, Binderup, Alekxander, Fahnøe, Ulrik, Hernandez, Carlos Rene Duarte, Gammeltoft, Karen Anbro, Bukh, Jens, Ryberg, Line Abildgaard, Tjørnelund, Helena Damtoft, Pham, Long V., Duarte Hernandez, Carlos Rene, Offersgaard, Anna, Gottwein, Judith Margarete   +14 more
core   +1 more source

A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

Journal of Cardiothoracic Surgery
Background Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients.
Chien-Ming Lo, Wei-Hsun Chen, Meng-Yun Tsai, Hung-I Lu, Yu-Hsin Hsiao, Kai-Hao Chuang, Yu Chen, Hsuan-Feng Wu, Kuo-Tung Huang, Yi-Hsi Wang   +9 more
doaj   +1 more source

Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Nature Communications
Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection.
Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Sophelia H. S. Chan, Eric H. Y. Lau, Benjamin J. Cowling, Gabriel M. Leung   +6 more
doaj   +1 more source

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Drugs - Real World Outcomes
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir ...
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, Suresh Kumar Chidambaram, Mohan Dass Pathmanathan, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +14 more
doaj   +1 more source

Nirmatrelvir: from discovery to modern and alternative synthetic approaches [PDF]

The global urgency in response to the COVID-19 pandemic has catalyzed extensive research into discovering efficacious antiviral compounds against SARS-CoV-2.
Michela Galli, Valerio Fasano, Daniele Passarella, Francesco Migliano, Alessandra Silvani, Andrea Citarella   +5 more
core   +1 more source

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19

Microbiology Spectrum
Immunocompromised individuals are susceptible to severe coronavirus disease 2019 and potentially contribute to the emergence of variants with altered pathogenicity due to persistent infection.
Rebekah Penrice-Randal, Eleanor G. Bentley, Parul Sharma, Adam Kirby, I'ah Donovan-Banfield, Anja Kipar, Daniele F. Mega, Chloe Bramwell, Joanne Sharp, Andrew Owen, Julian A. Hiscox, James P. Stewart   +11 more
doaj   +1 more source

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

PLoS ONE
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety.
Ji Sun, Xuanyu Deng, Juanjuan Huang, Gefei He, Shiqiong Huang   +4 more
doaj   +1 more source

Selective Inhibition of Vascular Smooth Muscle Cell Function by COVID-19 Antiviral Drugs: Impact of Heme Oxygenase-1

Antioxidants
Coronavirus disease 2019 (COVID-19) causes cardiovascular complications, which contributes to the high mortality rate of the disease. Emerging evidence indicates that aberrant vascular smooth muscle cell (SMC) function is a key driver of vascular disease
Kelly J. Peyton, Giovanna L. Durante, William Durante   +2 more
doaj   +1 more source

Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients:A target trial emulation study [PDF]

Background Molnupiravir and nirmatrelvir-ritonavir have demonstrated efficacy in reducing hospitalization and mortality among unvaccinated, high-risk COVID-19 outpatients. However, their impact on hospitalized adults remains unclear.
Boyuan Wang, Wang, Boyuan, Wong, Ian Chi Kei, Wing Ming Chu, Chan, Esther Wai Yin, Kwok Yung Yuen, Eric Yuk Fai Wan, Ian Chi Kei Wong, Yuen, Kwok Yung, Choi, Ming Hong, Esther Wai Yin Chan, Chu, Wing Ming, Ivan Fan Ngai Hung, Xu, Yahui, Yahui Xu, Ming Hong Choi, Wan, Eric Yuk Fai, Anthony Raymond Tam, Hung, Ivan Fan Ngai, Tam, Anthony Raymond   +19 more
core   +1 more source